Morten Orebo Holmström

Medicine & Life Sciences

1. Calreticulin 100%
2. T-Lymphocytes 88%
3. Neoplasms 74%
4. Vaccination 51%
5. Arginase 50%
6. Mutation 46%
7. Vaccines 41%
8. Peptides 37%
9. Exons 33%
10. Subunit Vaccines 31%
11. Primary Myelofibrosis 29%
12. INCB018424 28%
13. Epitopes 27%
14. Tumor Microenvironment 25%
15. Hematologic Neoplasms 24%
16. Ligands 22%
17. Therapeutics 20%
18. Interferons 20%
19. Cancer Vaccines 19%
20. Tissue Donors 18%
21. Antigens 18%
22. Interferon-alpha 18%
23. Transforming Growth Factors 16%
24. Polycythemia Vera 15%
25. Pancreatic Neoplasms 14%
26. Follicular Lymphoma 13%
27. Blood Platelets 13%
28. Calnexin 11%
29. Philadelphia Chromosome 11%
30. Immunosuppressive Agents 11%
31. Major Histocompatibility Complex 10%
32. Nivolumab 10%
33. Indoleamine-Pyrrole 2,3,-Dioxygenase 10%
34. Galectin 3 10%
35. Immunoglobulin Heavy Chains 10%
36. Regulatory T-Lymphocytes 10%
37. Alleles 9%
38. Cellular Immunity 8%
39. Antibodies 8%
40. Thrombocytopenia 8%
41. B-Cell Chronic Lymphocytic Leukemia 8%
42. Residual Neoplasm 8%
43. Immunity 8%
44. Immunotherapy 8%
45. Blocking Antibodies 8%
46. Adaptive Immunity 7%
47. Clinical Trials 7%
48. Melanoma 7%
49. Genes 7%
50. Bispecific Antibodies 7%